Vimian Group AB (publ) (VIMGF)
OTC Markets OTCPK · USD · Healthcare · Diagnostics & Research
$2.77 (+0.00%) as of
Key statistics
- Market cap
- 1.46B
- P/E (TTM)
- 39.57
- EPS (TTM)
- 0.0700
- 52-week range
- 2.6800 – 3.0100
- Beta
- 1.13
- Revenue (TTM)
- 466.9M
- Profit margin
- 8.40%
- Volume
- 7.00k
About Vimian Group AB (publ)
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, education, and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and surgical and dental products to veterinary clinics and universities, including dentistry and companion animal orthopedics under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Stockholm, Sweden
- Employees
- 1,025
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.